References
- Baker S D, Grochow L B, Donehower R C. Should anticancer drug doses be adjusted in the obese patient? J Natl Cancer Inst. 1995; 87: 333–334
- Poikonen P, Blomqvist C, Joensuu H. Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. Acta Oncol 2001; 40: 67–71
- Blouin R A, Warren G W. Pharmacokinetic considerations in obesity. J Pharm Sci 1999; 88: 1–7
- Cheymol G. Clinical pharmacokinetics of drugs in obesity: an update. Clin Pharmacokinet 1993; 25: 103–114
- Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000; 39: 215–231
- Graubner UB, Schmidt P, Nathrath S, et al. Maligne lymphoma im kindesalter. Tumorzentrum München; c2006 [cited 2006 Nov 16], Available from: http://www.krebsinfo.de/ki/empfehlung/lymphome/
- Mosteller R D. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098
- Palm C, Björk O, Björkholm M, Eksborg S. Quantification of doxorubicin in plasma: a comparative study of capillary and venous blood sampling. Anti-Cancer Drugs 2001; 12: 859–864
- Eksborg S, Söderhäll S, Frostvik-Stolt M, Lindberg A, Liliemark E. Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children. Anti-Cancer Drugs 2000; 11: 237–241
- Eksborg S. Anthracycline pharmacokinetics: limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin). Acta Oncol 1990; 29: 339–342
- Eksborg S, Palm C, Björk O. A comparative pharmacokinetic study of doxorubicin and 4′-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure. Anti-Cancer Drugs 2000; 11: 129–136
- Fleming R A, Eldridge R M, Johnson C E, Stewart C F. Disposition of high-dose methotrexate in an obese cancer patient. Cancer 1991; 68: 1247–1250
- Cox J, Penn N, Masood M, Hancock A K, Parker D. Drug overdose: a hidden hazard of obesity. J R Soc Med 1987; 80: 708–709
- Rodvold K A, Rushing D A, Tewksbury D A. Doxorubicin clearance in the obese. J Clin Oncol 1988; 6: 1321–1327
- Eksborg S, Hardell L, Bengtsson N O, Sjödin M, Elfsson B. Epirubicin as a single agent therapy for the treatment of breast cancer: a pharmacokinetic and clinical study. Med Oncol Tumor Pharmacother 1992; 9: 75–80
- Rogers P C, Meacham L R, Oeffinger K C, Henry D W, Lange B J. Obesity in pediatric oncology. Pediatr Blood Cancer 2005; 45: 881–891
- Navarro W H. Impact of obesity in the setting of high-dose chemotherapy. Bone Marrow Transplant 2003; 31: 961–966
- Griggs J J, Sorbero M E, Lyman G H. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005; 165: 1267–1273
- Eksborg S, Strandler H S, Edsmyr F, Näslund I, Tahvanainen P. Pharmacokinetic study of i.v. infusions of adriamycin. Eur J Clin Pharmacol 1985; 28: 205–212
- Frost B M, Eksborg S, Björk O, et al. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol 2002; 38: 329–337
- Palle J, Frost B M, Peterson C, et al. Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs 2006; 17: 385–392
- Bachur N R, Steele M, Meriwether W D, Hildebrand R C. Cellular pharmocodynamics of several anthrocycline antibiotics. J Med Chem 1976; 19: 651–654
- Itoh K, Sasaki Y, Fujii H, et al. Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer. Clin Cancer Res 2000; 6: 4082–4090
- Boos J, Real E, Schulze-Westhof E, et al. Investigation of the variability of etoposide pharmacokinetics in children. Int J Clin Pharmacol Ther Toxicol 1992; 30: 495–497
- Palle J, Frost B M, Gustafsson G, et al. Etoposide pharmacokinetics in children treated for acute myeloid leukemia. Anticancer Drugs 2006; 17: 1087–1094
- Boos J, Krumpelmann S, Schulze-Westhoff P, et al. Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? J Clin Oncol. 1995; 13: 2954–2960